tirzepatide singapore (Mounjaro) medication for weight loss in DKSH Singapore Approves Mounjaro Tirzepatide

The GIP component of this co-agonist pair has recently been found to provide unique benefits including, but not limited to, blockade of GLP-1-induced nausea and vomiting, weight-independent insulin sensitization, augmented insulin secretion, and lowering of triglycerides through a mechanism distinct from selective GLP-1RAs 2125

Also, its highly advisable to avoid doubling up on doses, as this can increase the risk of side effects like nausea, vomiting, or low blood sugar

doi: 10.3389/fmed.2020.00458 3 AydemirD.UlusuN

10.1016/j.ymgme.2015.09.004 Mol Genet Metab

FDA Creates 'Green List' of GLP-1 Drug Ingredients Approved for Entry in the U.S